出品|远见资本局作者|远见君随着年报季进入尾声,上市中药企业的业绩已经相继披露,整体来看,市场呈现两极分化的态势,几家欢喜几家忧。广州白云山医药集团股份有限公司(以下简称“白云山”)无疑属于“忧”的一方。这家老牌药企虽然仍坐在中药企业的头把交椅,其统治地位却已经出现动摇。—01—营收停滞,利润大幅缩水2024年,白云山实现营业收入749.93亿元,同比微降0.69%;实现归属净利润为28.35亿元...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.